Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

被引：0
|
作者：
Daniel M. Huse
Margaret von Mehren
Gregory Lenhart
Heikki Joensuu
Charles Blanke
Weiwei Feng
Stan Finkelstein
George Demetri
机构：
[1] Thomson Medstat,Department of Medical Oncology
[2] Fox Chase Cancer Center,Department of Oncology, Helsinki University
[3] Helsinki University Central Hospital,MIT Sloan School of Management
[4] The Oregon Health and Science University Cancer Institute,Dana
[5] Novartis Pharmaceuticals Corporation,Farber Cancer Institute
[6] Oncology,undefined
[7] Harvard-MIT Division of Health Sciences and Technology,undefined
[8] Center for Sarcoma and Bone Oncology,undefined
来源：
Clinical Drug Investigation | 2007年 / 27卷
关键词：
Pancreatic Cancer; Imatinib; National Comprehensive Cancer Network; National Comprehensive Cancer Network; Imatinib Mesylate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is partly dependent on reimbursement by third-party payers in many countries. The objective of this study was to estimate the cost effectiveness of imatinib mesylate in the treatment of GIST.
引用
收藏
页码：85 / 93
页数：8
相关论文
共 50 条
  • [1] Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours
    Huse, Daniel M.
    von Mehren, Margaret
    Lenhart, Gregory
    Joensuu, Heikki
    Blanke, Charles
    Feng, Weiwei
    Finkelstein, Stan
    Demetri, George
    CLINICAL DRUG INVESTIGATION, 2007, 27 (02) : 85 - 93
  • [2] Imatinib mesylate in treatment of advanced gastrointestinal stromal tumours
    Petricevic, B
    Vrbanec, D
    Belev, B
    Plestina, S
    Herceg, D
    Dedic-Plavetic, N
    ANNALS OF ONCOLOGY, 2005, 16 : 313 - 313
  • [3] Imatinib mesylate - In the treatment of gastrointestinal stromal tumours
    Croom, KF
    Perry, CM
    DRUGS, 2003, 63 (05) : 513 - 522
  • [4] Imatinib mesylate in the management of gastrointestinal stromal tumours (GIST)
    Kurteva G.P.
    Kurtev P.F.
    memo - Magazine of European Medical Oncology, 2010, 3 (2) : 49 - 52
  • [5] Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET
    Jager, PL
    Gietema, JA
    van der Graaf, WTA
    NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (05) : 433 - 438
  • [6] Imatinib mesylate in the treatment of gastrointestinal stromal tumour
    Steinert, DM
    McAuliffe, JC
    Trent, JC
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (01) : 105 - 113
  • [7] Imatinib mesylate for the treatment of gastrointestinal stromal tumor
    Cassier, Philippe A.
    Blay, Jean-Yves
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (05) : 623 - 634
  • [8] MUTATIONAL ANALYSIS BEFORE AND AFTER NEOADJUVANT IMATINIB MESYLATE FOR LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMOURS
    Lemke, M.
    Ko, Y. H.
    Law, C.
    Haid, V.
    Rowsell, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 490 - 490
  • [9] Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
    Gauden, Ruth
    Gauden, Stan
    CASE REPORTS IN ONCOLOGY, 2011, 4 (01): : 204 - 210
  • [10] COST-EFFECTIVENESS OF IMATINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST): CANADIAN PERSPECTIVE
    El Ouagari, K.
    Huse, D. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
12345